The 5 most recent market catalysts affecting $ANIK, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 7, 2026
Corporate Catalyst
Bullish
Impact 85
Anika Therapeutics Reports Third Quarter 2026 Financial Results and Raises 2026 Guidance
Anika Therapeutics reported a 10% increase in Q3 2026 revenue to $30.6 million, leading them to raise the lower end of their full-year revenue guidance and increase adjusted EBITDA…
Nov 6, 2026
Corporate Catalyst
Neutral
Impact 75
Anika Therapeutics Reports Third Quarter 2026 Financial Results
Anika Therapeutics announced its third-quarter 2026 financial results, revealing a 10% increase in total revenue to $30.6 million compared to the prior year. This growth was attrib…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 60
B. Riley Securities Maintains Buy on Anika Therapeutics, Raises Price Target to $21
B. Riley Securities analyst Anderson Schock has maintained a 'Buy' rating on Anika Therapeutics (ANIK) and raised the price target from $18 to $21. This action signals increased co…
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 85
Anika Therapeutics shares are trading higher after the company reported better-than-expected Q2 sales results and raised its FY26 sales guidance with its midpoint above estimates.
This headline represents a strong positive corporate catalyst for Anika Therapeutics. Better-than-expected sales demonstrate current operational strength, while raising future guid…
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 75
Anika Therapeutics Raises FY2026 Sales Guidance from $114.000M-$122.500M to $118.460M-$124.101M vs $118.612M Est
Anika Therapeutics (ANIK) has revised its FY2026 sales outlook upwards, moving from a range of $114.000M-$122.500M to $118.460M-$124.101M. This is significant because the new guida…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.